ALL

View All

CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia
Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL)

DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflic...

Find More

Acute lymphoblastic leukemia
Snippet : Acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from solid tumours, metastases of ALL seldom involve the parenchyma but are isolated to the leptomeninges, which is an infrequent site for carcinomatous invasion. Although metastasis to the CNS occur...

Find More

Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults

Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has an...

Find More